BRAF Mutation Detection Assay Earmarked for New PCR-based Molecular Diagnostics System
By LabMedica International staff writers Posted on 28 Oct 2014 |
A fully automated real-time PCR based molecular diagnostics system and a dedicated assay that identifies cancers driven by the BRAF oncogene recently received European CE marking certification.
The recently launched Biocartis (Mechelen, Belgium) Idylla instrument is the backbone of the company's flagship molecular diagnostics system. Along with Idylla, Biocartis also released the Idylla BRAF Mutation Test for detection of mutations in the BRAF oncogene.
The BRAF (v-Raf murine sarcoma viral oncogene homolog B1) gene encodes the protein serine/threonine-protein kinase B-Raf. About half of melanomas express the BRAFV600E mutation (at amino acid position number 600 on the B-Raf protein, the normal valine is replaced by glutamic acid). Inhibitors of B-Raf such as vemurafenib have been approved for the treatment of metastatic melanoma since August 2011. In addition to melanoma this mutation has been widely observed in papillary thyroid carcinoma and colorectal cancer.
The Idylla system is expected to establish a new standard for molecular diagnostic testing. The instrument's access on-demand design allows clinicians to initiate a new test at any given time, without the need for batching or for trained operators. The system’s short turnaround time—between 35 and 120 minutes—enables laboratories to report same-day results, significantly speeding up the treatment decision process. Idylla utilizes liquid-tight, disposable cartridges that reduce of risk of contamination and eliminate the necessity for separate pre- or post-PCR labs.
The BRAF Mutation Test is Idylla’s first oncology test and is designed to determine the most appropriate treatment for specific types of skin cancer. The assay can detect mutations directly from formalin-fixed paraffin-embedded (FFPE) tissue slices in about 90 minutes. This direct processing of FFPE tissue slices was cited as being unique for BRAF testing.
“Molecular testing plays a key role in the treatment decision process. It allows doctors to select specifically designed therapies based on the genetic profile of their patient,” said Rudi Pauwels, CEO of Biocartis. “Traditionally, molecular diagnostics involves a series of specialized, labor-intensive, and time-consuming steps. As a result, most labs do not perform these tests in-house, but send them to specialized labs where they are batched, often delaying treatment decisions. We are convinced that Idylla will completely transform the day-to-day practice in molecular labs, making molecular testing more straightforward than ever imagined. This will significantly speed up the diagnostic process and will enable doctors to make therapy decisions in a much shorter time frame. Ultimately, patients will receive a personalized therapy faster, ultimately improving treatment outcomes.”
Related Links:
Biocartis
The recently launched Biocartis (Mechelen, Belgium) Idylla instrument is the backbone of the company's flagship molecular diagnostics system. Along with Idylla, Biocartis also released the Idylla BRAF Mutation Test for detection of mutations in the BRAF oncogene.
The BRAF (v-Raf murine sarcoma viral oncogene homolog B1) gene encodes the protein serine/threonine-protein kinase B-Raf. About half of melanomas express the BRAFV600E mutation (at amino acid position number 600 on the B-Raf protein, the normal valine is replaced by glutamic acid). Inhibitors of B-Raf such as vemurafenib have been approved for the treatment of metastatic melanoma since August 2011. In addition to melanoma this mutation has been widely observed in papillary thyroid carcinoma and colorectal cancer.
The Idylla system is expected to establish a new standard for molecular diagnostic testing. The instrument's access on-demand design allows clinicians to initiate a new test at any given time, without the need for batching or for trained operators. The system’s short turnaround time—between 35 and 120 minutes—enables laboratories to report same-day results, significantly speeding up the treatment decision process. Idylla utilizes liquid-tight, disposable cartridges that reduce of risk of contamination and eliminate the necessity for separate pre- or post-PCR labs.
The BRAF Mutation Test is Idylla’s first oncology test and is designed to determine the most appropriate treatment for specific types of skin cancer. The assay can detect mutations directly from formalin-fixed paraffin-embedded (FFPE) tissue slices in about 90 minutes. This direct processing of FFPE tissue slices was cited as being unique for BRAF testing.
“Molecular testing plays a key role in the treatment decision process. It allows doctors to select specifically designed therapies based on the genetic profile of their patient,” said Rudi Pauwels, CEO of Biocartis. “Traditionally, molecular diagnostics involves a series of specialized, labor-intensive, and time-consuming steps. As a result, most labs do not perform these tests in-house, but send them to specialized labs where they are batched, often delaying treatment decisions. We are convinced that Idylla will completely transform the day-to-day practice in molecular labs, making molecular testing more straightforward than ever imagined. This will significantly speed up the diagnostic process and will enable doctors to make therapy decisions in a much shorter time frame. Ultimately, patients will receive a personalized therapy faster, ultimately improving treatment outcomes.”
Related Links:
Biocartis
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Technology News
- New Diagnostic System Achieves PCR Testing Accuracy
- DNA Biosensor Enables Early Diagnosis of Cervical Cancer
- Self-Heating Microfluidic Devices Can Detect Diseases in Tiny Blood or Fluid Samples
- Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible
- First of Its Kind Technology Detects Glucose in Human Saliva
- Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop
- Novel Noninvasive Test Detects Malaria Infection without Blood Sample
- Portable Optofluidic Sensing Devices Could Simultaneously Perform Variety of Medical Tests
- Point-of-Care Software Solution Helps Manage Disparate POCT Scenarios across Patient Testing Locations
- Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents
- Breakthrough Test Detects Biological Markers Related to Wider Variety of Cancers
- Rapid POC Sensing Kit to Determine Gut Health from Blood Serum and Stool Samples
- Device Converts Smartphone into Fluorescence Microscope for Just USD 50
- Wi-Fi Enabled Handheld Tube Reader Designed for Easy Portability